Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Not yet recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

not_yet_recruiting250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

NCT07410520
not_yet_recruitingphase_2

Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

NCT07353476
not_yet_recruitingphase_2

PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

NCT07267234
recruitingearly_phase_1

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

NCT06106152

Clinical Trials (4)

Showing 4 of 4 trials
NCT07410520Phase 2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Recruiting
NCT07353476Phase 2

Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

Not Yet Recruiting
NCT07267234Phase 2

PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

Not Yet Recruiting
NCT06106152Early Phase 1

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4